Differential Diagnosis of Tauopathies – a Clinical Approach
Authors:
R. Rusina 1,2; R. Matěj 3,4; E. Růžička 1; J. Roth 1
Authors‘ workplace:
Neurologická klinika a Centrum klinických neurověd, 1. LF UK a VFN v Praze
1; Neurologické oddělení, Thomayerova nemocnice, Praha
2; Oddělení patologie a molekulární medicíny, Thomayerova nemocnice, Praha
3; Ústav patologie, 3. LF UK v Praze
4
Published in:
Cesk Slov Neurol N 2015; 78/111(5): 526-534
Category:
Review Article
doi:
https://doi.org/10.14735/amcsnn2015526
Overview
Tauopathies are neurodegenerative disorders characterized by accumulation of abnormally modified forms of the tau-protein, predominantly in frontal, temporal and parietal cortical regions, basal ganglia and in the midbrain. Tauopathies are well defined from the molecular biological and biochemical point of view; clinical symptoms may be, however, heterogeneous. Common signs of frontotemporal lobar degenerations include a more or less prominent syndrome of frontotemporal dementia. On the other hand, the clinical picture of frontotemporal dementia may not be caused by a tauopathy only; in many cases the underlying etiopathogenic cause is different. The aim of our review is to classify the relationship between tauopathies and frontotemporal lobar degenerations. This review contains a proposal of a practical approach to refining clinical diagnosis of the different tauopathies.
Key words:
neurodegeneration – tauopathy – frontotemporal lobar degeneration –progressive supranuclear palsy – progressive aphasia – corticobasal syndrome
The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.
The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.
Sources
1. Spillantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet Neurol 2013; 12(6): 609– 622. doi: 10.1016/ S1474‑ 4422(13)70090‑ 5.
2. Peden AH, Ironside JW. Molecular pathology in neurodegenerative diseases. Curr Drug Targets 2012; 13(12): 1548– 1559.
3. Williams DR. Tauopathies: classification and clinical update on neurodegenerative diseases associated with microtubule‑associated protein tau. Intern Med J 2006; 36(10): 652– 660.
4. Williams DR, Holton JL, Strand C, Pittman A, de Silva R, Lees AJ et al. Pathological tau burden and distribution distinguishes progressive supranuclear palsy‑ parkinsonism from Richardson‘s syndrome. Brain 2007; 130(6): 1566– 1576.
5. Rademakers R, Neumann M, Mackenzie IR. Advances in understanding the molecular basis of frontotemporal dementia. Nat Rev Neurol 2012; 8(8): 423– 434. doi: 10.1038/ nrneurol.2012.117.
6. Rohan Z, Matej R. Current concepts in the classification and diagnosis of frontotemporal lobar degenerations: a practical approach. Arch Pathol Lab Med 2014; 138(1): 132– 138. doi: 10.5858/ arpa.2012‑ 0510‑ RS.
7. Grossman M. The non‑fluent/ agrammatic variant of primary progressive aphasia. Lancet Neurol 2012; 11(6): 545– 555. doi: 10.1016/ S1474‑ 4422(12)70099‑ 6.
8. Dickson DW, Rademakers R, Hutton ML. Progressive supranuclear palsy: pathology and genetics. Brain Pathol 2007; 17(1): 74– 82.
9. Mathew R, Bak TH, Hodges JR. Diagnostic criteria for corticobasal syndrome: a comparative study. J Neurol Neurosurg Psychiatry 2012; 83(4): 405– 410. doi: 10.1136/ jnnp‑ 2011‑ 300875.
10. Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF,Abner EL, Alafuzoff I et al. Primary age‑related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol 2014; 128(6): 755– 766. doi: 10.1007/ s00401‑ 014‑ 1349‑ 0.
11. Josephs KA, Petersen RC, Knopman DS, Boeve BF, Whitwell JL, Duffy JR et al. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology 2006; 66(1): 41– 48.
12. Litvan I, MacIntyre A, Goetz CG, Wenning GK, Jellinger K, Verny M et al. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol 1998; 55(7): 969– 978.
13. Onyike CU, Diehl‑ Schmid J. The epidemiology of frontotemporal dementia. Int Rev Psychiatry 2013; 25(2): 130– 137. doi: 10.3109/ 09540261.2013.776523.
14. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J et al. Sensitivity of revised diagnostic criteria for the behavioral variant of frontotemporal dementia. Brain 2011; 134(9): 2456– 2477. doi: 10.1093/ brain/ awr179.
15. Gorno‑ Tempini ML, Hillis AE, Weintraub S, Kertesz A,Mendez M, Cappa SF et al. Classification of primary progressive aphasia and its variants. Neurology 2011; 76(11): 1006– 1014. doi: 10.1212/ WNL.0b013e31821103e6.
16. Josephs KA, Duffy JR, Strand EA, Machulda MM, Senjem ML, Master AV et al. Characterizing a neurodegenerative syndrome: primary progressive apraxia of speech. Brain 2012; 135(5): 1522– 1536. doi: 10.1093/ brain// aws032.
17. Wadia PM, Lang AE. The many faces of corticobasal degeneration. Parkinsonism Relat Disord 2007; 13 (Suppl 3): S336– S340. doi: 10.1016/ S1353‑ 8020(08)70027‑ 0.
18. Hassan A, Whitwell JL, Josephs KA. The corticobasal syndrome – Alzheimer‘s disease conundrum Expert Rev Neurother 2011; 11(11): 1569– 1578. doi: 10.1586/ ern.11.153.
19. Johanidesová S, Rusina R, Houška P, Keller J, Matěj R.Alzheimerova nemoc probíhající pod obrazem kortikobazální degenerace – kazuistika. Cesk Slov Neurol N 2012; 75/ 108(3): 373– 377.
20. Ling H, O’Sullivan SS, Holton JL, Revesz T, Massey LA, Williams DR et al. Does corticobasal degeneration exist? A clinicopathological re‑evaluation. Brain 2010; 133(7): 2045– 2057. doi: 10.1093/ brain/ awq123.
21. Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical supranuclear gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 1964; 10: 333– 359.
22. Liscic RM, Srulijes K, Gröger A, Maetzler W, Berg D. Differentiation of progressive supranuclear palsy: clinical, imaging and laboratory tools. Acta Neurol Scand 2013; 127(5): 362– 370. doi: 10.1111/ ane.12067.
23. Menšíková K, Kaňovský P, Kaiserová M, Nestrašil I, Bareš M. Proměnlivá tvář parkinsonské neurodegenerace. Cesk Slov Neurol N 2013; 76/ 109(1): 26– 34.
24. Respondek G, Roeber S, Kretzschmar H, Troakes C, Al‑ Sarraj S, Gelpi E et al. Accuracy of the National Institute for Neurological Disorders and Stroke/ Society for Progressive Supranuclear Palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the diagnosis of progressive supranuclear palsy. Mov Disord 2013; 28(4): 504– 509. doi: 10.1002/ mds.25327.
25. Richardson JC, Steele J, Olszewski J. Supranuclear ophthalmoplegia, pseudobulbar palsy, nuchal dystonia and dementia. A clinical report on eight cases of „heterogenous system degeneration“. Trans Am Neurol Assoc 1963; 88: 25– 29.
26. Williams DR, de Silva R, Paviour DC, Pittman A, Watt HC,Kilford L et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson‘s syndrome and PSP‑ parkinsonism. Brain 2005; 128(6): 1247– 1258.
27. Imai H, Nakamura T, Kondo T, Narabayashi H. Dopa‑ unresponsive pure akinesia or freezing. A condition within a wide spectrum of PSP? Adv Neurol 1993; 60: 622– 625.
28. Williams DR, Holton JL, Strand K, Revesz T, Lees AJ. Pure akinesia with gait freezing: a third clinical phenotype of progressive supranuclear palsy. Mov Disord 2007; 22(15): 2235– 2241.
29. Josephs KA, Boeve BF, Duffy JR, Smith GE, Knopman DS,Parisi JE et al. Atypical progressive supranuclear palsy underlying progressive apraxia of speech and nonfluent aphasia. Neurocase 2005; 11(4): 283– 296.
30. Thal DR, Schultz C, Botez G, Del Tredici K, Mrak RE, Griffin WS et al. The impact of argyrophilic grain disease on the development of dementia and its relationship to concurrent Alzheimer‘s disease‑related pathology. Neuropathol Appl Neurobiol 2005; 31(3): 270– 279.
31. Matěj R, Koukolík F. Nemoc s argyrofilními zrny: kazuistické sdělení prvních dvou případů diagnostikovaných v ČR a přehled literatury. Cesk Patol 2006; 42(2): 66– 70.
32. Rosen HJ, Gorno‑ Tempini ML, Goldman W, Perry RJ, Schuff N, Weiner M et al. Pattern of brain atrophy in frontotemporal dementia and semantic dementia. Neurology 2002; 58(2): 198– 208.
33. Rusz J, Bonnet C, Klempíř J, Tykalová T, Baborová E,Novotný M et al. Speech disorders reflect differing pathophysiology in Parkinson’s disease, progressive supranuclear palsy and multiple system atrophy. J Neurol 2015; 262(4): 992– 1001. doi: 10.1007/ s00415‑ 015‑ 7671‑ 1.
34. Dugger BN, Adler CH, Shill HA, Caviness J, Jacobson S, Driver‑ Dunckley E et al. Concomitant pathologies among a spectrum of parkinsonian disorders. Parkinsonism Relat Disord 2014; 20(5): 525– 529. doi: 10.1016/ j.parkreldis.2014.02.012.
35. Rusina R, Pazdera L, Kulišťák P, Vyšata O, Matěj R. Pick and Alzheimer diseases: a rare comorbidity presenting as corticobasal syndrome. Cogn Behav Neurol 2013; 26(4): 189– 194. doi: 10.1097/ WNn.0000000000000011.
36. Menšíková K, Matěj R, Tučková L, Rusina R, Ehrmann J, Kaňovský P. Progressive supranuclear palsy phenotype mimicking synucleinopathies. J Neurol Sci 2013; 329(1– 2): 34– 37. doi: 10.1016/ j.jns.2013.03.008.
37. Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele‑ Richardson‑ Olszewski syndrome): report of the NINDS‑ SPSP international workshop. Neurology 1996; 47(1): 1– 9.
Labels
Paediatric neurology Neurosurgery NeurologyArticle was published in
Czech and Slovak Neurology and Neurosurgery
2015 Issue 5
Most read in this issue
- Diagnostic in Patient with Acute Vertigo
- Recurrent Transient Global Amnesia – Four Case Reports
- Normative Data for the Rey‑ Osterrieth Complex Figure Test in Older Czech Adults
- Contribution of Olfactory Tests to Diagnosis of Neurodegenerative Diseases